Abstract
Parthenogenetic embryonic stem (pES) cells are pluripotent stem cells derived from artificially activated oocytes without embryo destruction, thus eliciting less ethic concerns, and have been demonstrated promising for autologous stem cell therapy. However, pES cells could carry inappropriate imprinting such as relatively high expression of H19, a paternal imprinted gene, and may negatively influence their lineage differentiation. We show that knockdown of H19 by shRNA in mouse pES cells does not alter self-renewal and expression of genes associated with pluripotency. We find that down-regulation of H19 promotes differentiation of pES cells to epidermis. In addition, H19 depletion also facilitates differentiation of pES cells to cardiomyocytes and strong heart-like beating. Our data support the notion that reduction of H19 improves pES cell differentiation in the lineages of ectoderm and mesoderm, and provide further evidence suggesting that defective imprinting can be manipulated to allow potential application of pES cells for stem cell therapy.
Keywords: Differentiation, H19, parthenogenetic stem cells.
Current Molecular Medicine
Title:Knockdown of H19 Enhances Differentiation Capacity to Epidermis of Parthenogenetic Embryonic Stem Cells
Volume: 14 Issue: 6
Author(s): Y. Yin, H. Wang, K. Liu, F. Wang, X. Ye, M. Liu, R. Xiang, N. Liu and L. Liu
Affiliation:
Keywords: Differentiation, H19, parthenogenetic stem cells.
Abstract: Parthenogenetic embryonic stem (pES) cells are pluripotent stem cells derived from artificially activated oocytes without embryo destruction, thus eliciting less ethic concerns, and have been demonstrated promising for autologous stem cell therapy. However, pES cells could carry inappropriate imprinting such as relatively high expression of H19, a paternal imprinted gene, and may negatively influence their lineage differentiation. We show that knockdown of H19 by shRNA in mouse pES cells does not alter self-renewal and expression of genes associated with pluripotency. We find that down-regulation of H19 promotes differentiation of pES cells to epidermis. In addition, H19 depletion also facilitates differentiation of pES cells to cardiomyocytes and strong heart-like beating. Our data support the notion that reduction of H19 improves pES cell differentiation in the lineages of ectoderm and mesoderm, and provide further evidence suggesting that defective imprinting can be manipulated to allow potential application of pES cells for stem cell therapy.
Export Options
About this article
Cite this article as:
Yin Y., Wang H., Liu K., Wang F., Ye X., Liu M., Xiang R., Liu N. and Liu L., Knockdown of H19 Enhances Differentiation Capacity to Epidermis of Parthenogenetic Embryonic Stem Cells, Current Molecular Medicine 2014; 14 (6) . https://dx.doi.org/10.2174/1566524014666140724101035
DOI https://dx.doi.org/10.2174/1566524014666140724101035 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
QT Prolongation and Safety in the Indian Population
Current Drug Safety Sirolimus and its Analogs and its Effects on Vascular Diseases
Current Pharmaceutical Design MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Hepatic Effects of Duloxetine-II: Spontaneous Reports and Epidemiology of Hepatic Events
Current Drug Safety Protein-Energy Malnutrition Alters Hippocampal Plasticity-Associated Protein Expression following Global Ischemia in the Gerbil
Current Neurovascular Research Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination
Current Pharmaceutical Design Sirolimus: A Novel Immunosuppressive Drug in Heart Transplantation
Recent Patents on Cardiovascular Drug Discovery Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Epigenetic Mechanisms in Alzheimer's Disease
Current Medicinal Chemistry Cell-penetrating Peptides as Nucleic Acid Delivery Systems: From Biophysics to Biological Applications
Current Pharmaceutical Design Retinal Protein O-GlcNAcylation and the Ocular Renin-angiotensin System: Signaling Cross-roads in Diabetic Retinopathy
Current Diabetes Reviews Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Interleukin (IL) 5 for Asthma and Hypereosinophilic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence
Current Drug Targets Quantitative Imaging Biomarkers and their Emerging Role
Current Medical Imaging Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies
Current Vascular Pharmacology Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy